

KASIC NEWSLETTER

Issue One, Volume Four

Pictured Top: Natural Bridge State Resort Park
Attribution to kentuckytourism.com



Connecting the DOTS for *Staphylococcus aureus* bacteremia

The Dalbavancin for Treatment of *S. aureus* Bacteremia (DOTS) trial was recently published in JAMA. This is an open-label randomized controlled trial which included 200 patients with complicated *S. aureus* bacteremia from a wide range of sources including osteomyelitis, septic thrombophlebitis, and right sided endocarditis.

Patients were randomized to standard of care intravenous antibiotic regimens or a 2-dose dalbavancin regimen. Dalbavancin was NOT superior to standard of care therapy using a desirability of outcome ranking (DOOR) primary outcome comprised of clinical success, infectious complications, safety complications, mortality, and health-related quality of life. Dalbavancin was non-inferior to standard of care in clinical efficacy. No outcome differences were observed in subgroups, including by baseline pathogen (majority of patients had MSSA bacteremia). **Standard of care regimens and dalbavancin appear to be comparable options for the treatment of complicated *S. aureus* bacteremia.**

[Click here to read the study!](#)

#FIGHT FLU



Influenza Recommendations for 2025-2026 Flu Season

Flu season is once again upon us, and it is time to receive the annual influenza vaccination. The Advisory Committee on Immunization Practices recommends that all individuals 6 months or older with no contraindications receive their annual influenza vaccination. Ideally individuals are encouraged to receive their vaccine during September or October to provide coverage through the entire flu season. Detailed recommendations are available on the CDC's website.

[Click here for more
from the CDC!](#)



KASIC Cases

Each week, a fictional case describing a common antimicrobial stewardship opportunity is posted on X (formerly Twitter) and LinkedIn. Participants are encouraged to answer the poll first and then review the best answer along with an explanation.

Ready to test your antimicrobial stewardship knowledge?

Try out the latest case:

A patient is admitted with a dental abscess. Blood cultures grow Viridans Group Streptococcus (VGS) that is susceptible to penicillin. Is cephalexin and metronidazole a good oral stepdown option to complete therapy?

- A. Yes
- B. No



[Click here for the BEST answer](#)

[Read more cases here](#)

[Follow KASIC on Twitter & LinkedIn](#)

Latest Clinical Education Pearls: Click to Read!

[Species Spotlight: *Citrobacter koseri* & *Citrobacter amalonaticus*](#)

[Don't Let the Bug Beat You: *E. casseliflavus* and *E. gallinarum*](#)

[Penicillins for *Staphylococcus aureus*: Aye or Nay?](#)

[Ceftriaxone Guided IV to PO](#)

[Don't Let the Bug Beat You: Viridans Group Streptococci](#)

Norton Infectious Diseases Institute Grand Rounds Educational Series

[Vexed by Viruses: Viral Illness and Antimicrobial Stewardship](#)

[Highly Pathogenic Avian Influenza A\(H5N1\)](#)

[Risks of Antimicrobial Use](#)

[Infection Prevention and Control for Fire EMS](#)

[Click here for Grand Rounds Information](#)